Northern Trust Corp Contrafect Corp Transaction History

Northern Trust Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	BUY	$3.19 - $4.43 $32,818 - $45,575	10,288 Added 17.47%	69,180 $280,000
Q2 2021 Aug 13, 2021	SELL	$3.58 - $4.9 $718,362 - $983,234	-200,660 Reduced 77.31%	58,892 $259,000
Q1 2021 May 12, 2021	SELL	$4.46 - $6.68 $1.05 Million - $1.58 Million	-236,016 Reduced 47.63%	259,552 $1.25 Million
Q4 2020 Feb 11, 2021	BUY	$5.05 - $6.4 $1.16 Million - $1.47 Million	229,629 Added 86.35%	495,568 $2.5 Million
Q3 2020 Nov 16, 2020	BUY	$5.05 - $6.99 $372,841 - $516,071	73,830 Added 38.43%	265,939 $1.4 Million
Q2 2020 Aug 14, 2020	BUY	$4.69 - $7.81 $774,647 - $1.29 Million	165,170 Added 613.13%	192,109 $1.23 Million
Q1 2020 May 14, 2020	BUY	$5.5 - $12.3 $148,164 - $331,349	26,939 New	26,939 $155,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.